REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 | RESCEU Project | H2020 | CORDIS

Objective

RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk groups. RESCEU brings together academia, national public health agencies and EFPIA with proven expertise and a strong track record in RSV research. The academic partners are leaders in RSV epidemiology, clinical RSV research, health economics, and vaccinology; and key opinion leaders with advisory roles in European and national public health bodies, health technology agencies and vaccine advisory groups. EFPIA participants (AZ, GSK, JPNV, Novavax, Pfizer, and SP) have active clinical research programmes to develop lead candidates for treatment and prevention of RSV in infants, adults and the elderly. As part of RESCEU, EFPIA participants will contribute expertise in a wide range of fields including infectious disease, clinical medicine, immunology, epidemiology, biostatistics, biomarker development, global health, and health economics. RESCEU’s aim is to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics. RESCEU aims to provide sustainable longer term impact on RSV disease burden and thus make a significant contribution to improved health and wellbeing in Europe.
The project will comprise 6 work packages. WP 1-3 will identify and marshal data from large-scale systematic reviews of epidemiological and cost studies, disease registries, linked routine (national) healthcare and claims datasets and will establish a framework for and assemble data from RSV surveillance in Europe to estimate RSV disease burden on health services and inform economic models.

Field of science

/medical and health sciences/health sciences/epidemiology
/medical and health sciences/health sciences/public and environmental health/epidemics prevention/modeling of disease spread

Programme(s)

H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

IMI2-2015-06-02 - Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences

Call for proposal

H2020-JTI-IMI2-2015-06-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

THE UNIVERSITY OF EDINBURGH

Address

Old College, South Bridge
EH8 9YL Edinburgh
United Kingdom

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 3 604 782,74

REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019